. 2017 Jan 16;19(1):21–35. doi: 10.1007/s10198-016-0864-4

Table 8.

Probabilistic sensitivity analysis results (per patient)

Comparisons	Mean total cost (£)	Mean total QALYs	Mean incremental cost (95% CrI) (£)	Mean incremental QALY (95% CrI)	ICER (95% CrI) (£ per QALY)	Probability of cost-effectiveness (%)^a
LDX vs	3379.34	0.725	–8.14 (−403.88 to 363.51)	0.006 (–0.011 to 0.031)	Dominant (undefined, undefined)^b	61
MPH-ER	3387.48	0.718	–8.14 (−403.88 to 363.51)	0.006 (–0.011 to 0.031)	Dominant (undefined, undefined)^b	61
LDX vs	3377.19	0.723	−195.58 (−675.95 to 269.06)	0.009 (−0.012 to 0.043)	Dominant (undefined, undefined)	80
ATX	3572.77	0.714	−195.58 (−675.95 to 269.06)	0.009 (−0.012 to 0.043)	Dominant (undefined, undefined)	80

ATX atomoxetine, CrI credible interval, ICER incremental cost-effectiveness ratio, LDX lisdexamfetamine dimesylate, MPH-ER methylphenidate extended release, QALY quality-adjusted life year

^aAt £20,000 per QALY

^bThe CrIs for probabilistic ICER estimates are not defined when these estimates are spread over multiple quadrants of the cost-effectiveness plane